SCHEMBL3920090

SCHEMBL3920090

CCCCCc1ccc(C(=O)N2CCN(C3CCC3)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 4/20 0.60
L3MBTL3 Q96JM7 8/20 0.58
L3MBTL1 Q9Y468 6/20 0.58
SPHK1 Q9NYA1 5/20 0.53
SPHK2 Q9NRA0 3/20 0.53
MBTD1 Q05BQ5 3/20 0.52
TP53BP1 Q12888 1/20 0.52
L3MBTL4 Q8NA19 1/20 0.52
KDM4E B2RXH2 2/20 0.52
POLB P06746 1/20 0.52
ALDH1A1 P00352 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3917908 0.96 HRH3 (0.61) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL3923604 0.91 HRH3 (0.64) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL20922362 0.88 L3MBTL3 (0.67) L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4
SCHEMBL3922239 0.85 HRH3 (0.67) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL10264586 0.83 L3MBTL3 (0.69) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL18978543 0.83 ALDH1A1 (0.62) SPHK1SPHK2ALDH1A1
SCHEMBL3772494 0.82 HRH3 (0.57) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL3926615 0.81 HRH3 (0.68) HRH3L3MBTL3L3MBTL1MBTD1TP53BP1
SCHEMBL15923369 0.81 SPHK1 (0.63) SPHK1SPHK2
SCHEMBL6715256 0.81 HPGD (0.66) SPHK1SPHK2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038269-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-25 EP claimed
US-20080045507-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-21 US claimed
WO-2008002816-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 WO claimed
US-20080045507-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-21 US disclosed
US-20080045507-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-21 US disclosed
US-20080045507-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-02-21 US disclosed
WO-2008002816-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045507-A1 SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR HRH3, HRH4, HRH2 HRH3 1/4885L3MBTL3 2202/4885L3MBTL1 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.